Group items tagged

The International Congress for the History of Pharmacy is a biennial meeting of historians, pharmacists and other researchers and health professionals from around the world interested in the history of pharmacy and pharmaceuticals. This year's Congress is co-sponsored by AIHP and the International Society for the History of Pharmacy, and is supported by a generous grant from the United States Pharmacopeial Convention (USP). The conference will be held in Washington, DC, at the Capital Hilton, on September 5-8, 2019. The theme of the Congress is "The Pharmacist and Quality Medicines." Four plenary lectures and more than 50 papers will focus on a broad range of topics related to all aspects of history of pharmacy and medicines, including the training and regulation of pharmacists and the social, scientific, technologic, and economic aspects of pharmaceuticals and the pharmaceutical industry. The conference will be of interest to scholars in the history of pharmacy and medicine and related fields. Plenary lectures will be given by noted historians William B. McAllister, Jacalyn Duffin, Michael Flannery, and Lucas Richert. The full conference schedule is available here. The conference website can be found here.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support screening of target-based pharmaceutical libraries to identify candidate therapeutics against select eukaryotic pathogens and subsequent preclinical development activities.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support screening of target-based pharmaceutical libraries to identify candidate therapeutics against select eukaryotic pathogens and subsequent preclinical development activities.

The National Toxicology Program (NTP) was established within the Department of Health and Human Services and charged with coordinating toxicological testing programs within the Public Health Service of the Department. The NTP, as part of the National Institute of Environmental Health Sciences (NIEHS), is responsible for evaluating the toxic and carcinogenic potential of environmental agents that may pose a health hazard to citizens of the United States. The NTP requires support for the conduct of short- and long-term toxicity and carcinogenicity studies following exposure to a variety of test agents by various routes of exposure. This requirement is designed to study diverse agents that may include: environmental chemicals; chemicals used in manufacturing or industrial settings; naturally occurring chemicals; food additives, preservatives, colorants or flavorings; pharmaceuticals, botanically- and non botanically-based dietary supplements; herbicides, fungicides, and pesticides; ingredients found in a wide variety of consumer products including soaps, lotions, perfumes and cosmetics; chemicals used in detergents and cleaners, etc.; naturally occurring and synthetic fibers, nanomaterials including carbon nanotubes; metals; plasticizers; flame retardants; mold or mold components; or other agents not specified at this time.

The S&R Foundation Ryuji Ueno Award for Ion Channels or Barrier Function Research was established in 2007 by the American Physiological Society through the generous support of Ryuji Ueno, M.D., Ph.D., Sachiko Kuno, Ph.D., and S&R Foundation.  Dr. Ueno and Dr. Kuno are founders of Sucampo Pharmaceuticals, Inc., and S&R Foundation, both in Bethesda, Maryland. The Ryuji Ueno Award is given annually to an individual demonstrating outstanding promise based on his/her research in ion channels or epithelial barrier function. Applications are accepted from APS members who hold an academic rank of assistant professor or higher or a comparable position if the member is not affiliated with an academic institution. The award of $30,000 is designated for use in the ion channels or epithelial barrier function research program in which the awardee is conducting his/her research. The award does not include any indirect cost reimbursement. The recipient receives complimentary registration to attend the Experimental Biology Meeting and a plaque presented at the Society's Business Meeting. The recipient is expected to attend a Founders' dinner immediately following the APS Business Meeting.

The Chemical and Biological Separations (CBS) program supports fundamental research on novel methods and materials for separation processes.  These processes are central to the chemical, biochemical, materials, energy, and pharmaceutical industries.  A fundamental understanding of the interfacial, transport, and thermodynamic behavior of multiphase chemical systems as well as quantitative descriptions of processing characteristics in the process-oriented industries is critical for efficient resource management and effective environmental protection.  The program encourages proposals that address emerging research areas and technologies, have a high degree of interdisciplinary thought coupled with knowledge creation, and integrate education and research. Research topics OF PARTICULAR INTEREST in CBS include fundamental molecular-level work on: Nanostructured materials for separations Biorenewable resource separation processes Purification of drinking water Field (flow, magnetic, electrical) induced separations Separation of molecular constituents from blood The duration of unsolicited awards is generally one to three years.  The average annual award size for the program is $80,000.  Proposals requesting a substantially higher amount than this, without prior consultation with the Program Director, may be returned without review.  Small equipment proposals of less than $100,000 will also be considered and may be submitted during the annual submission window. 

To continue making safe and effective topical semisolid drug products available to the American public, it is essential that FDA's regulatory science, as well as best practices in the pharmaceutical industry, are informed by the most current understanding of the product quality attributes that are potentially critical to the therapeutic performance of topical semisolid dosage forms. The scope of this project is to characterize all measurable physical/chemical qualities of different dosage forms of semisolid topical drug products, identify appropriate methodologies for measuring each of these quality attributes, characterize formulation and manufacturing parameters that alter the arrangement of matter in the dosage form as measured by specific quality attributes, and utilize in vitro and/or in vivo measures of product performance to correlate variations in critical quality attributes with a failure mode for a drug product.  

The ALS Therapy Alliance was established in 2000 to facilitate ALS research projects and collaborations among a diverse group of scientists and clinicians at multiple institutions working to cure amyotrophic lateral sclerosis. The alliance represents a unique collaborative enterprise that spans multiple laboratories, universities, and disciplines.   Today, the ATA partners with corporations, biotech and pharmaceutical firms, manufacturers, and the media to create awareness and raise funds for ALS research through its annual Breakthrough ALS campaign. To date, more than $30 million has been raised to fund research for finding a cure for this devastating disease.   The ALS Therapy Alliance is accepting applications from investigators for ALS research projects. Grants ranging from $100,000 to $1 million over one to three years will be awarded to projects -- including but not limited to basic, clinical, and translational research and clinical trials - aimed at developing a better understanding of, or treatments for, ALS.   National and international nonprofit organizations and for-profit companies are eligible to apply.

This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Cooperative Agreement (U01) Research Projects for research on the identification of small molecule or biologic lead compounds that are excellent candidates for therapeutic development. The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. The scope of research supported by this FOA includes confirmation of molecular targets for therapeutic development, demonstration of in vitro activity of candidate therapeutics, preliminary in vivo proof-of-concept efficacy data, preliminary adsorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) evaluations and pharmacokinetics/pharmacodynamics (PK/PD) data. These studies should result in the identification of at least one lead compound ready for optimization. Lead compounds are biologically active and synthetically feasible compounds where specificity, affinity, potency, target selectivity, efficacy, and safety have been established. Lead compounds should be ready for more advanced development under possible support from other programs such as the one described in the companion FOA "CounterACT Optimization of Therapeutic Lead Compound (U01)" (PAR-18-NNN). The scope of this FOA encompasses Technical Readiness Level (TRL) 1-3 - see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan.

NineSigma, representing a Japanese leading pharmaceutical company, seeks drug discovery projects which make use of any of the following drug discovery underlying technologies and which are in a hit discovery stage. It is preferable that the research has already started; however, proposals are welcome also from an organization with plans to start a specific project in the future. The client aims to build a drug discovery platform, which is globally competitive, through collaboration with partners. The client can provide opportunities, depending on the R&D stage and the business plan of partners, and hopes not only to foster joint research and development, but also to maximize outcome creation by licensing, support with budget, etc. to support improvement of underlying technology.

The Beckman Center for the History of Chemistry at the Chemical Heritage Foundation, an independent research library in Philadelphia, is inviting applications for short- or long-term fellowships in the history of science, technology, medicine, and industry. The research collections at CHF range chronologically from the fifteenth century to the present and include six thousand rare books, significant archival holdings, thousands of images, and a large artifact and fine arts collection, supported by over one hundred thousand reference volumes and journals. Within the collections there are many areas of special strength, including alchemy, mining & metallurgy, dyeing and bleaching, balneology, gunpowder and pyrotechnics, gas-lighting, books of secrets, inorganic and organic chemistry, biochemistry, food chemistry, and pharmaceuticals.

The AKC Canine Health Foundation supports novel and multi-disciplinary approaches to addressing the health needs of all dogs.  We are continuing our commitment to canine health by seeking to fund critical research to diagnose, prevent and/or treat allergic diseases in dogs, including the molecular profiling of canine atopic dermatitis (CAD). CHF is seeking innovative approaches to canine atopy, with a primary goal of the studies supported by this request to include the identification of novel immune signaling targets involved in pathophysiology of CAD, and to further validate and prioritize a next generation of pharmaceutical or vaccine targets of which agonism or antagonism might improve the lives of dogs with CAD.

The Alzheimer's Drug Discovery Foundation is accepting Letters of Intent for its ADDF-Harrington Scholar Program, which seeks to accelerate innovative research with the potential to prevent, treat, or cure Alzheimer's disease or related dementias. The award will provide recipients with both research funding and committed project support by a team of pharmaceutical industry experts. The program aims to support hit-to-lead optimization through investigational new drug (IND)-enabling studies. Award amounts will average $600,000 over two years. In 2019, drug targets related to proteostatis are of high priority, including but not limited to autophagy, lysosomal biogenesis, proteasomal degradation, post-translational modifications associated with proteostasis, protein folding/misfolding, endoplasmic reticulum stress, and extracellular clearance. Other novel targets are encouraged, including but not limited to neuroprotection, inflammation, vascular function, mitochondria and metabolic function, APOE, and epigenetics.

The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement applications for research that advances promising compounds thorough the drug development pipeline for the treatment of Alcohol Use Disorder (AUD). NIAAA is seeking applications for medications development research projects from both for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, small businesses not eligible for the SBIR/STTR program and single entities able to demonstrate significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. The aim of this FOA is to move candidate compounds through Investigational New Drug (IND) requirements, Phase 1 human safety, tolerability, and dosing studies, and Phase 2 human laboratory and proof-of-concept trials. Within these phases of drug development, each proposed project should have a defined entry and exit point. Finally, this FOA will not support animal studies to prove efficacy of the candidate compound unless required by the Food and Drug Administration or peer review. Applicants are strongly encouraged to contact the NIAAA Division of Medications Development Staff prior to submitting to this FOA.

This call is open to all respondents, and we particularly encourage proposals from the private sector and/or entities that have partnerships with the private sector - to ensure a pathway to commercialization at scale. Our first principle is to leverage existing innovation within the food and beverage industry and its suppliers for new applications that can reach low-income consumers, for greatest scale and impact. We also welcome technologies and translational approaches based on knowledge from ancillary fields, e.g., veterinary science, pharmaceuticals, etc.

The purpose of this project is to develop and implement a virtual bioequivalence trial simulation platform that can be used to perform population-based statistical analysis in complex and computationally intensive physiologically based pharmacokinetic (PBPK) models developed to describe the absorption, distribution and elimination of active pharmaceutical ingredients formulated in complex and non-complex dosage forms administered via oral or non-oral routes. The developed virtual bioequivalence trial simulation platform will be used to generate predictions on the in vivo drug product performance, to perform bioequivalence assessments between brand name and generic drug products and to inform regulatory decisions relating to generic drug development.

The purpose of this project is to develop and implement a virtual bioequivalence trial simulation platform that can be used to perform population-based statistical analysis in complex and computationally intensive physiologically based pharmacokinetic (PBPK) models developed to describe the absorption, distribution and elimination of active pharmaceutical ingredients formulated in complex and non-complex dosage forms administered via oral or non-oral routes. The developed virtual bioequivalence trial simulation platform will be used to generate predictions on the in vivo drug product performance, to perform bioequivalence assessments between brand name and generic drug products and to inform regulatory decisions relating to generic drug development.

Pharmaceutical company AmerisourceBergen created the AmerisourceBergen Foundation as a separate not-for-profit charitable organization with the aim of supporting health and education-related causes that enrich the lives of its global community. To accomplish that goal, the foundation provides funding for programs and organizations focused on expanding access to quality healthcare - both human and animal - around the world. In the view of the foundation, the current epidemic of opioid abuse and misuse is a crisis that demands attention, action, and accountability. Understanding the need for expediency, the foundation is inviting grant-funded nonprofit organizations to submit proposals that describe how it can best contribute resources and funding to address opioid abuse and misuse. Grants will be awarded for the most innovative and constructive solutions in one of two key areas of focus: safe disposal and education around prevention. Applicants are strongly encouraged to identify and leverage existing, proven, evidence-based frameworks and strategies, as well as existing tools and materials, but may also propose original and innovative projects. Applications focused on education may address a spectrum of needs, but priority will be given to the effective dissemination of the following topics: provider education about appropriate opioid prescribing; patient education about the risks and effects of prescription opioids, and what to do if they have concerns about addiction; public education, especially aimed at rural communities; training to reduce youth risk factors (such as delinquency) and boost protective factors (such as decision-making skills for problem solving and resisting peer pressure; addiction as a childhood onset condition; preventing teens from initiating problematic opioid use in the first place; and advising parents of teens to lock up prescription opioid medications and dispose of old pills.

NineSigma, representing a Japanese pharmaceutical company, seeks a drug seeds for developing novel, oral, low-molecular weight, drugs for treating chronic kidney disease (CKD).

Currently, the drugs are designed in such a way that the active pharmaceutical ingredient (API) is immediately released in the stomach and absorbed in the bloodstream, rapidly relieving the patient from his/her pain (left-hand side). In case multiple doses are taken all at once, a (potentially toxic) supratherapeutic amount of API immediately gets into the user's bloodstream (center). This amount is illicitly used to induce euphoria and could be potentially toxic. Grünenthal's intention is to design a drug formulation that guarantees the API's release profile in case of proper therapeutical usage. However, in case multiple drug units are taken, the release of API, that is available for absorption (right-hand side), will be limited or, at least, decreased to avoid overdosing.